Plain-English translation of NCT06726577 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing whether , a new medication given by intravenous injection, is safe and effective for treating amyotrophic lateral sclerosis (ALS). The study will compare the medication to a placebo (a saline injection with no active drug) to see if the new treatment helps slow disease progression or improve symptoms. All participants will also continue taking their standard ALS medication during the trial.
ALS is a serious disease that gradually weakens muscles over time, and current treatment options are limited. This trial is being conducted to find out whether this new medication could offer patients a potentially more effective way to manage their condition.
You likely qualify if…
You likely don't qualify if…
You will attend study visits over approximately 29 weeks. First, there is a 1-week screening period. Then you will receive intravenous injections either of the new medication or a placebo for 12 weeks (in 3 cycles of 4 weeks each), followed by 12 more weeks where all participants receive the active medication. Throughout the trial, you will continue taking your regular ALS medication and undergo safety assessments and blood work. Some participants may also have additional blood tests to measure how the body processes the medication.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China